These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. [Parkinson disease. Directed use of modern therapy]. Möller JC; Wächter T; Oertel WH MMW Fortschr Med; 2001 May; 143 Suppl 2():45-50. PubMed ID: 11434257 [TBL] [Abstract][Full Text] [Related]
44. Drug therapy of Parkinson's disease. An overview. Mizuno Y Eur Neurol; 1992; 32 Suppl 1():3-8. PubMed ID: 1358614 [TBL] [Abstract][Full Text] [Related]
45. [Development of disease-modifying drugs for Parkinson's disease. Is it a tough road?]. Nagai M Nihon Yakurigaku Zasshi; 2023 May; 158(3):223-227. PubMed ID: 36990797 [TBL] [Abstract][Full Text] [Related]
46. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease. Fernandez HH; Chen JJ Pharmacotherapy; 2007 Dec; 27(12 Pt 2):174S-185S. PubMed ID: 18041937 [TBL] [Abstract][Full Text] [Related]
47. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Deleu D; Northway MG; Hanssens Y Clin Pharmacokinet; 2002; 41(4):261-309. PubMed ID: 11978145 [TBL] [Abstract][Full Text] [Related]
48. [The role of dopaminagonists in the treatment of Parkinson's disease]. Ransmayr G Praxis (Bern 1994); 2005 Oct; 94(42):1633-8. PubMed ID: 16277084 [TBL] [Abstract][Full Text] [Related]
49. Off spells and dyskinesias: pharmacologic management of motor complications. Khan TS Cleve Clin J Med; 2012 Jul; 79 Suppl 2():S8-13. PubMed ID: 22761271 [TBL] [Abstract][Full Text] [Related]
50. Designing prodrugs for the treatment of Parkinson's disease. Sozio P; Cerasa LS; Abbadessa A; Di Stefano A Expert Opin Drug Discov; 2012 May; 7(5):385-406. PubMed ID: 22494466 [TBL] [Abstract][Full Text] [Related]
51. New and emerging treatments for Parkinson disease. Fung VS Med J Aust; 2015 Apr; 202(6):283-4. PubMed ID: 25832138 [No Abstract] [Full Text] [Related]
52. Effective strategies in the management of Parkinson's disease. Wills AJ Hosp Med; 1998 Apr; 59(4):287-90. PubMed ID: 9722367 [TBL] [Abstract][Full Text] [Related]
53. [Drug therapy of Parkinson's disease]. Myllylä V Duodecim; 1997; 113(18):1827-34. PubMed ID: 10892076 [No Abstract] [Full Text] [Related]
54. Dopaminergic agonists in the treatment of Parkinson's disease: a review. Piccoli F; Riuggeri RM J Neural Transm Suppl; 1995; 45():187-95. PubMed ID: 8748625 [TBL] [Abstract][Full Text] [Related]
55. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists. Kondo T J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060 [TBL] [Abstract][Full Text] [Related]
56. [Rasagiline in monotherapy in patients with early stages of Parkinson's disease and in combined and adjunct therapy to levodopa with moderate and advanced stages]. Pagonabarraga J; Rodríguez-Oroz MC Rev Neurol; 2013 Jan; 56(1):25-34. PubMed ID: 23250679 [TBL] [Abstract][Full Text] [Related]
57. Drug treatment of Parkinson's disease. Quinn N BMJ; 1995 Mar; 310(6979):575-9. PubMed ID: 7888935 [TBL] [Abstract][Full Text] [Related]
58. Parkinson's disease. Clarke C; Moore AP Clin Evid; 2002 Jun; (7):1208-20. PubMed ID: 12230738 [No Abstract] [Full Text] [Related]
59. [A current view on dopamine receptor agonists in the treatment of Parkinson's disease]. Titova NV Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(9):76-83. PubMed ID: 26525820 [TBL] [Abstract][Full Text] [Related]
60. Current and experimental treatments of Parkinson disease: A guide for neuroscientists. Oertel W; Schulz JB J Neurochem; 2016 Oct; 139 Suppl 1():325-337. PubMed ID: 27577098 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]